Keywords
Dyslipidemia
Network pharmacology
Molecular docking
Submitted : 2024-04-17
Accepted : 2024-05-02
Published : 2024-05-17
Abstract
Objective: To explore the mechanism of intervention of Fangxiangxiaozhi prescription on dyslipidemia by using network pharmacology and molecular docking. Methods: The traditional Chinese Medicine Systems Pharmacology Database and Analysis Platform (TCMSP), Pubchem, Uniprot, and other databases were adopted to screen the active ingredients and the corresponding targets of Fangxiangxiaozhi prescription. Dyslipidemia-related targets were identified using the databases of Disgenet and GeneCards. Then, the intersection target of drugs and diseases was demonstrated via a Venn diagram. Cytoscape3.7.2 was used to construct a “drugs-active ingredients-intersection targets” network map and the key active ingredients with the top 7-degree values were determined. The protein interaction network and topology analysis of the intersection target genes were carried out by combining STRING11.0 and Cytoscape3.7.2. Moreover, the gene ontology (GO) and the Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis of the intersection target genes were carried out using the Metascape database. Lastly, the key active ingredients and targets were molecular docked by AutoDockTools, Pymol, and other software. Results: There were 51 active components and 509 target genes of which 74 intersect with dyslipidemia. The key targets included tumor necrosis factor (TNF), interleukin-6 (IL-6), AKT1, PPAR gamma (PPARG), VEGFA, and PPARα. GO enrichment analysis obtained 1040 biological processes, 33 cell components, and 84 molecular functions; KEGG enrichment analysis obtained 148 pathways. The molecular docking results showed that the key targets and compounds exhibited good binding force. Conclusion: The active ingredients of Fangxiangxiaozhi prescription regulated several pathways through multiple targets to intervene in dyslipidemia. This study can serve as a foundation for further research.
References
He C, Fu P, Zhang K, et al., 2018, Chinese Herbal Medicine for Dyslipidemia: Protocol for A Systematic Review and Meta-Analysis. Medicine (Baltimore), 97(44): e13048.
Yuan C, Zhang X, Long X, et al., 2019, Effect of Beta-Sitosterol Self-Microemulsion and Beta-Sitosterol Ester with Linoleic Acid on Lipid-Lowering in Hyperlipidemic Mice. Lipids Health Dis, 18(1): 157.
Hosseini A, Razavi BM, Banach M, et al., 2021, Quercetin and Metabolic Syndrome: A Review. Phytother Res, 35(10): 5352–5364.
Yi H, Peng H, Wu X, et al., 2021, The Therapeutic Effects and Mechanisms of Quercetin on Metabolic Diseases: Pharmacological Data and Clinical Evidence. Oxid Med Cell Longev, 2021: 6678662.
Feng Z, Wang C, Yue J, et al., 2021, Kaempferol-induced GPER Upregulation Attenuates Atherosclerosis via the PI3K/AKT/Nrf2 Pathway. Pharm Biol, 59(1): 1106–1116.
Hoang MH, Jia Y, Lee JH, et al., 2019, Kaempferol Reduces Hepatic Triglyceride Accumulation by Inhibiting Akt. J Food Biochem, 43(11): e13034.
Lu X, Chen H, Dong P, et al., 2010, Phytochemical Characteristics and Hypoglycaemic Activity of Fraction from Mushroom Inonotus obliquus. J Sci Food Agric, 90(2): 276–280.
Kaur J, 2014, A Comprehensive Review on Metabolic Syndrome. Cardiol Res Pract, 2014: 943162.
Chen X, Xun K, Chen L, et al., 2009, TNF-alpha, A Potent Lipid Metabolism Regulator. Cell Biochem Funct, 27(7): 407-416.
Panteleeva AA, Razgildina ND, Brovin DL, et al., 2021, The Expression of Genes Encoding ABCA1 and ABCG1 Transporters and PPARgamma, LXRbeta, and RORalpha Transcriptional Factors in Subcutaneous and Visceral Adipose Tissue in Women with Metabolic Syndrome. Mol Biol (Mosk), 55(1): 64–74.
Giuliani A, Montesanto A, Matacchione G, et al., 2022, The Association between Single Nucleotide Polymorphisms, including miR-499a Genetic Variants, and Dyslipidemia in Subjects Treated with Pharmacological or Phytochemical Lipid-Lowering Agents. Int J Mol Sci, 23(10): 5617.
Duval C, Muller M, Kersten S, 2007, PPAR? and Dyslipidemia. Biochim Biophys Acta, 1771(8): 961-971.
Tsigos C, Chrousos GP, 2002, Hypothalamic-pituitary-adrenal axis, Neuroendocrine Factors and Stress. J Psychosom Res, 53(4): 865–871.
Ormazabal V, Nair S, Elfeky O, et al., 2018, Association Between Insulin Resistance and The Development of Cardiovascular Disease. Cardiovasc Diabetol, 17(1): 122.
Hurtubise J, Mclellan K, Durr K, et al., 2016, The Different Facets of Dyslipidemia and Hypertension in Atherosclerosis. Curr Atheroscler Rep, 18(12): 82.
Rodriguez A, Ezquerro S, Mendez-Gimenez L, et al., 2015, Revisiting the Adipocyte: A Model for Integration of Cytokine Signaling in The Regulation of Energy Metabolism. Am J Physiol Endocrinol Metab, 309(8): 691–714.
Cao N, Li X, Zhang W, et al., 2022, Research Progress of Signaling Pathways of The Natural Substances Intervene Dyslipidemia (Review). Exp Ther Med, 24(2): 494.
Deverse JS, Sandhu AS, Mendoza N, et al., 2013, Shear Stress Modulates VCAM-1 Expression in Response to TNF-? and Dietary Lipids via Interferon Regulatory Factor-1 in Cultured Endothelium. Am J Physiol Heart Circ Physiol, 305(8): 1149–1157.